Revenue · FY 2026
₹58,462 Cr
▲ 11.19% YoY
Computed EBITDA · FY 2026
₹19,703 Cr
▲ 14.31% YoY
Net profit · FY 2026
₹11,509 Cr
▲ 4.96% YoY
Authorised capital
₹617.97 Cr
Registered with MCA
Paid-up capital
₹239.93 Cr
Issued & subscribed
Open charges
₹16.06 Cr
Satisfied ₹1,785.22 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
16,436
Latest available
About Sun Pharmaceutical Industries Limited
Data last updated: 14 July 2026
Sun Pharmaceutical Industries Limited is a public limited company based in Vadodara, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 01 March 1993, the company has been in operation for over 33 years.
Registered with ROC Ahmedabad under CIN L24230GJ1993PLC019050. Listed on BSE: 524715 and NSE: SUNPHARMA.
Capital: an authorised share capital of ₹617.97 Cr and a paid-up capital of ₹239.93 Cr. It is led by directors including Pawan Kumar Goenka and Dilip Shantilal Shanghvi.
Last AGM: 31 July 2025. Financial statements filed for year ended 31 March 2025. Office: Sparc Tandalja, Vadodara, Gujarat, India – 390012.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹58,462 Cr, a growth of 11.19% compared to the previous year. The net worth stands at ₹83,880 Cr (up 15.72% YoY). Total assets are valued at ₹108,785 Cr (up 18.12% YoY).
The company has a workforce of approximately 16,436 employees as per the latest available data. Its group structure includes 14 subsidiaries.
The company is associated with 2 brands - Flore, Sun Pharma. As per MCA filings, the company has open charges of ₹16.06 Cr and satisfied charges of ₹1,785.22 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sunpharma.com.
Company Details of Sun Pharmaceutical Industries Limited
CIN
L24230GJ1993PLC019050
Registration Number
019050
Incorporation Date
01 March 1993
ROC
Ahmedabad
Listing Status
Listed (BSE: 524715, NSE: SUNPHARMA)
Company Status
Active
Date of Last AGM
31 July 2025
Date of Balance Sheet
31 March 2025
Compliance Status
Active Compliant
Key People
Kirti Wardhaman Ganorkar Managing Director
Dilip Shantilal Shanghvi Whole-Time Director
Vidhi Dilip Shanghvi Whole-Time Director
Contact Details
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressSparc Tandalja, Vadodara, Gujarat, India – 390012
-
IndustryPharma, Drug Formulation & Development, API Manufacturers
Company report
Sun Pharmaceutical Industries Limited - full intelligence report
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
₹799
₹999
20% off
Secure checkout · GST invoice included
Associated Brands with Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited operates two associated brands: Flore and Sun Pharma. These brands represent Sun Pharmaceutical Industries Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Customized probiotics for gut health are provided via stool analysis. | flore.com | |
| Specialty generic pharmaceuticals and APIs are manufactured and marketed. | sunpharma.com |
Competitors & Alternatives of Sun Pharmaceutical Industries Limited
Brands and companies operating in the same space as Sun Pharmaceutical Industries Limited include Viome, Evvy, Elo Health and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Viome
|
Machine learning-based bioinformatics solutions for health insights are provided. | Los Alamos, United States, United States | 2016 |
Evvy
|
Vaginal microbiome test kits are provided through an online platform. | New York, United States, United States | 2002 |
Elo Health
|
Personalized supplements are delivered based on biochemical analysis. | San Francisco, United States, United States | 2020 |
Rootine
|
Provider of personalized nutrition supplements | Nashville, United States, United States | 2018 |
Ombre
|
Microbiome-based personalized supplements are offered via gut testing kits. | San Francisco, United States, United States | 2016 |
iSplack
|
Athlete-focused body care products are manufactured with science-backed formulations. | Boulder, United States, United States | 2014 |
Jona
|
AI-powered microbiome profiling platform to improve digestive health | Hialeah, United States, United States | 2022 |
Wellnicity
|
Personalized diet and supplement recommendations are provided via genetic analysis. | Austin, United States, United States | 2002 |
uBiome
|
Provides comprehensive sequence datasets for human microbiome research and analysis. | San Francisco, United States, United States | 2012 |
Business Activity of Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details for Sun Pharmaceutical Industries Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is audited by S R B C & CO LLP (ICAI peer reviewed, certificate valid till 2029-02-28) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| S R B C & CO LLP (ICAI peer reviewed, certificate valid till 2029-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is currently managed by 9 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Pawan Kumar Goenka
Also directs:
Pmg Advisory Llp
|
Director | 21 May 2021 | 5 Years 2 Months | Current |
|
Dilip Shantilal Shanghvi
Also directs:
Sun Pharma Advanced Research Company Limited, Sun Petrochemicals Private Limited, Alfa Infraprop Private Limited and 3 more
|
Whole-Time Director | 01 Apr 2008 | 18 Years 3 Months | Current |
|
Gautam Bhailal Doshi
Also directs:
Bhavna Doshi Associates Llp, Piramal Finance Limited, Sun Pharma Laboratories Limited and 4 more
|
Director | 25 May 2018 | 8 Years 1 Months | Current |
|
Kirti Wardhaman Ganorkar
Also directs:
Sun Pharma Laboratories Limited, Sun Pharma Distributors Limited
|
Managing Director | 01 Sep 2025 | 0 Years 10 Months | Current |
| Vidhi Dilip Shanghvi | Whole-Time Director | 22 May 2025 | 1 Years 1 Months | Current |
|
Aalok Dilip Shanghvi
Also directs:
Shikha Learning Labs Private Limited
|
Whole-Time Director | 01 Jun 2023 | 3 Years 1 Months | Current |
Showing 6 of 9 current directors. View all directors
Financials of Sun Pharmaceutical Industries Limited FY 2026 filings available
Sun Pharmaceutical Industries Limited reported revenue of ₹58,462 Cr (up 11.19% YoY) for FY 2026.
Revenue · FY 2026
₹58,462 Cr
▲ 11.19%
Profit · FY 2026
₹11,509 Cr
▲ 4.96%
Computed EBITDA · FY 2026
₹19,703 Cr
▲ 14.31%
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹58,462 Cr | ₹52,578 Cr | ₹48,497 Cr | ₹43,886 Cr | ₹38,654 Cr | ₹32,838 Cr |
| Other Income | ₹1,971.72 Cr | ₹1,965.04 Cr | ₹1,354.19 Cr | ₹634.52 Cr | ₹921.51 Cr | ₹635.98 Cr |
| Total Income | ₹60,434 Cr | ₹54,543 Cr | ₹49,851 Cr | ₹44,520 Cr | ₹39,576 Cr | ₹33,473 Cr |
| Cost of Materials Consumed | ₹7,389.02 Cr | ₹6,449.1 Cr | ₹6,904.33 Cr | ₹7,777.57 Cr | ₹7,049.12 Cr | ₹5,515.23 Cr |
| Purchases of Stock-in-Trade | ₹3,811.53 Cr | ₹4,147.95 Cr | ₹3,466.15 Cr | ₹3,571.5 Cr | ₹3,410.03 Cr | ₹3,414.37 Cr |
| Changes in Inventories | ₹343.13 Cr | ₹150.31 Cr | ₹292.13 Cr | -₹686.91 Cr | -₹107.61 Cr | ₹300.85 Cr |
| Employee Benefit Expense | ₹11,419 Cr | ₹9,973.12 Cr | ₹9,429.06 Cr | ₹8,296.03 Cr | ₹7,300.83 Cr | ₹6,362.35 Cr |
| Finance Costs | ₹338.91 Cr | ₹231.36 Cr | ₹238.47 Cr | ₹172 Cr | ₹127.35 Cr | ₹302.73 Cr |
| Depreciation & Amortisation | ₹2,937.85 Cr | ₹2,575.39 Cr | ₹2,556.64 Cr | ₹2,529.43 Cr | ₹2,143.74 Cr | ₹2,052.78 Cr |
| Other Expenses | ₹17,768 Cr | ₹16,586 Cr | ₹15,382 Cr | ₹13,281 Cr | ₹10,604 Cr | ₹10,255 Cr |
| Total Expenses | ₹44,007 Cr | ₹40,114 Cr | ₹38,269 Cr | ₹34,940 Cr | ₹30,528 Cr | ₹28,203 Cr |
| Profit Before Exceptional Items & Tax | ₹16,426 Cr | ₹14,430 Cr | ₹11,582 Cr | ₹9,579.88 Cr | ₹9,048.14 Cr | ₹5,270.23 Cr |
| Exceptional Items | -₹1,307.48 Cr | -₹677.85 Cr | -₹494.32 Cr | -₹171.45 Cr | -₹4,566.82 Cr | -₹260.64 Cr |
| Profit Before Tax | ₹15,119 Cr | ₹13,752 Cr | ₹11,088 Cr | ₹9,408.43 Cr | ₹4,481.32 Cr | ₹5,009.59 Cr |
| Total Tax Expense | ₹3,554.36 Cr | ₹2,772.03 Cr | ₹1,439.45 Cr | ₹847.59 Cr | ₹1,075.5 Cr | ₹822.8 Cr |
| Net Profit | ₹11,509 Cr | ₹10,965 Cr | ₹9,610.03 Cr | ₹8,512.94 Cr | ₹3,389.28 Cr | ₹4,171.96 Cr |
| attributable to Owners | ₹11,479 Cr | ₹10,929 Cr | ₹9,576.38 Cr | ₹8,473.58 Cr | ₹3,272.73 Cr | ₹3,764.93 Cr |
| attributable to NCI | ₹29.23 Cr | ₹35.71 Cr | ₹33.65 Cr | ₹39.36 Cr | ₹116.55 Cr | ₹407.03 Cr |
| Other Comprehensive Income | ₹3,826.74 Cr | ₹912.41 Cr | ₹1,142.13 Cr | ₹2,256.57 Cr | ₹557.21 Cr | ₹2,120.83 Cr |
| Total Comprehensive Income | ₹15,335 Cr | ₹11,877 Cr | ₹10,752 Cr | ₹10,770 Cr | ₹3,946.49 Cr | ₹6,292.79 Cr |
| EBITDA (computed) | ₹19,703 Cr | ₹17,237 Cr | ₹14,377 Cr | ₹12,281 Cr | ₹11,319 Cr | ₹7,625.74 Cr |
| Basic EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 | ₹13.60 | ₹15.69 |
| Diluted EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 | ₹13.60 | ₹15.69 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹108,785 Cr | ₹92,101 Cr | ₹85,463 Cr | ₹80,744 Cr |
| Non-current Assets | ₹44,894 Cr | ₹39,476 Cr | ₹41,988 Cr | ₹40,860 Cr |
| Current Assets | ₹63,860 Cr | ₹52,594 Cr | ₹43,433 Cr | ₹39,862 Cr |
| Property, Plant & Equipment | ₹11,114 Cr | ₹10,036 Cr | ₹10,192 Cr | ₹10,390 Cr |
| Inventories | ₹11,493 Cr | ₹10,243 Cr | ₹9,868.29 Cr | ₹10,513 Cr |
| Trade Receivables | ₹15,510 Cr | ₹13,046 Cr | ₹11,249 Cr | ₹11,439 Cr |
| Cash & Equivalents | ₹9,770.51 Cr | ₹10,269 Cr | ₹9,285.65 Cr | ₹4,623.73 Cr |
| Equity (Net Worth) | ₹83,880 Cr | ₹72,486 Cr | ₹67,106 Cr | ₹59,315 Cr |
| Equity Share Capital | ₹239.93 Cr | ₹239.93 Cr | ₹239.93 Cr | ₹239.93 Cr |
| Borrowings (Non-current) | ₹31.26 Cr | ₹2.52 Cr | ₹1.33 Cr | ₹0 |
| Borrowings (Current) | ₹4,050.35 Cr | ₹1,867.11 Cr | ₹2,844.36 Cr | ₹6,197.88 Cr |
| Total Debt (computed) | ₹4,081.61 Cr | ₹1,869.63 Cr | ₹2,845.69 Cr | ₹6,197.88 Cr |
| Current Liabilities | ₹22,622 Cr | ₹18,194 Cr | ₹16,984 Cr | ₹19,906 Cr |
| Total Liabilities | ₹24,905 Cr | ₹19,615 Cr | ₹18,357 Cr | ₹21,428 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹12,419 Cr | ₹14,072 Cr | ₹12,135 Cr | ₹4,959.33 Cr | ₹8,984.54 Cr |
| Investing Cash Flow | -₹11,344 Cr | -₹5,306.16 Cr | -₹690.2 Cr | -₹7,943.68 Cr | -₹5,724.74 Cr |
| Financing Cash Flow | -₹2,512.55 Cr | -₹7,905.82 Cr | -₹6,710.16 Cr | ₹2,376.07 Cr | -₹5,193.46 Cr |
| Capital Expenditure | ₹3,609.37 Cr | ₹2,128.58 Cr | ₹2,201.81 Cr | ₹2,085.58 Cr | ₹1,495.04 Cr |
| Free Cash Flow (computed) | ₹8,809.81 Cr | ₹11,944 Cr | ₹9,933.17 Cr | ₹2,873.75 Cr | ₹7,489.5 Cr |
| Dividends Paid | ₹3,937.8 Cr | ₹3,617.3 Cr | ₹2,900.71 Cr | ₹2,519.73 Cr | ₹2,169.19 Cr |
| Net Change in Cash | -₹498.26 Cr | ₹983.12 Cr | ₹4,661.92 Cr | ₹115.48 Cr | -₹1,764.78 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹14,612 Cr | ₹15,521 Cr | ₹14,478 Cr | ₹13,851 Cr | ₹12,959 Cr | ₹13,675 Cr | ₹13,291 Cr | ₹12,653 Cr | ₹11,983 Cr | ₹12,381 Cr | ₹12,192 Cr | ₹11,941 Cr |
| Other Income | ₹458.5 Cr | ₹578.84 Cr | ₹469.92 Cr | ₹464.46 Cr | ₹612.87 Cr | ₹465.62 Cr | ₹354 Cr | ₹532.55 Cr | ₹605.94 Cr | ₹250.2 Cr | ₹293.61 Cr | ₹204.44 Cr |
| Total Income | ₹15,070 Cr | ₹16,099 Cr | ₹14,948 Cr | ₹14,316 Cr | ₹13,572 Cr | ₹14,141 Cr | ₹13,645 Cr | ₹13,185 Cr | ₹12,589 Cr | ₹12,631 Cr | ₹12,486 Cr | ₹12,145 Cr |
| Cost of Materials Consumed | ₹2,182.44 Cr | ₹1,813.48 Cr | ₹1,621.51 Cr | ₹1,771.59 Cr | ₹1,845.06 Cr | ₹1,408.31 Cr | ₹1,638.72 Cr | ₹1,557.01 Cr | ₹1,676.73 Cr | ₹1,709.66 Cr | ₹1,665.45 Cr | ₹1,852.49 Cr |
| Purchases of Stock-in-Trade | ₹753.34 Cr | ₹922.42 Cr | ₹1,087.79 Cr | ₹1,047.98 Cr | ₹1,036.73 Cr | ₹1,238.69 Cr | ₹875.1 Cr | ₹997.43 Cr | ₹982.88 Cr | ₹796.49 Cr | ₹1,006.82 Cr | ₹679.96 Cr |
| Changes in Inventories | -₹134.69 Cr | ₹209.2 Cr | ₹273.43 Cr | -₹4.81 Cr | -₹244.6 Cr | ₹93.54 Cr | ₹180.38 Cr | ₹120.99 Cr | -₹279.2 Cr | ₹230.79 Cr | ₹114.82 Cr | ₹225.72 Cr |
| Employee Benefit Expense | ₹2,960.41 Cr | ₹2,892 Cr | ₹2,764.79 Cr | ₹2,801.66 Cr | ₹2,488.52 Cr | ₹2,552.28 Cr | ₹2,477.7 Cr | ₹2,454.62 Cr | ₹2,299.34 Cr | ₹2,363.32 Cr | ₹2,364.36 Cr | ₹2,402.04 Cr |
| Finance Costs | ₹85.89 Cr | ₹78.36 Cr | ₹99.86 Cr | ₹74.8 Cr | ₹49.14 Cr | ₹51.51 Cr | ₹69.17 Cr | ₹61.54 Cr | ₹73.57 Cr | ₹34.73 Cr | ₹49.29 Cr | ₹80.88 Cr |
| Depreciation & Amortisation | ₹775.47 Cr | ₹732.33 Cr | ₹729.5 Cr | ₹700.55 Cr | ₹663.79 Cr | ₹630.56 Cr | ₹625.91 Cr | ₹655.13 Cr | ₹650.36 Cr | ₹622.14 Cr | ₹632.82 Cr | ₹651.32 Cr |
| Other Expenses | ₹4,896.09 Cr | ₹4,734.95 Cr | ₹4,203.74 Cr | ₹3,933.32 Cr | ₹4,117.04 Cr | ₹4,373.62 Cr | ₹4,180.53 Cr | ₹3,915.08 Cr | ₹4,268 Cr | ₹3,803.61 Cr | ₹3,861.58 Cr | ₹3,448.86 Cr |
| Total Expenses | ₹11,519 Cr | ₹11,383 Cr | ₹10,781 Cr | ₹10,325 Cr | ₹9,955.68 Cr | ₹10,349 Cr | ₹10,048 Cr | ₹9,761.8 Cr | ₹9,671.68 Cr | ₹9,560.74 Cr | ₹9,695.14 Cr | ₹9,341.27 Cr |
| Profit Before Exceptional Items & Tax | ₹3,551.34 Cr | ₹4,716.64 Cr | ₹4,167.61 Cr | ₹3,990.77 Cr | ₹3,616.03 Cr | ₹3,792.57 Cr | ₹3,597.88 Cr | ₹3,423.5 Cr | ₹2,917.16 Cr | ₹3,070.16 Cr | ₹2,790.88 Cr | ₹2,804.01 Cr |
| Exceptional Items | ₹0 | -₹489.48 Cr | ₹0 | -₹818 Cr | -₹361.68 Cr | -₹316.17 Cr | ₹0 | ₹0 | -₹101.64 Cr | -₹69.81 Cr | ₹0 | -₹322.87 Cr |
| Profit Before Tax | ₹3,551.34 Cr | ₹4,227.16 Cr | ₹4,167.61 Cr | ₹3,172.77 Cr | ₹3,254.35 Cr | ₹3,476.4 Cr | ₹3,597.88 Cr | ₹3,423.5 Cr | ₹2,815.52 Cr | ₹3,000.35 Cr | ₹2,790.88 Cr | ₹2,481.14 Cr |
| Total Tax Expense | ₹827.62 Cr | ₹826.07 Cr | ₹1,030.52 Cr | ₹870.15 Cr | ₹1,093.71 Cr | ₹558.86 Cr | ₹567.21 Cr | ₹552.25 Cr | ₹148.93 Cr | ₹432.32 Cr | ₹390.1 Cr | ₹468.1 Cr |
| Net Profit | ₹2,709.66 Cr | ₹3,381.17 Cr | ₹3,124.95 Cr | ₹2,292.87 Cr | ₹2,153.93 Cr | ₹2,912.98 Cr | ₹3,037.33 Cr | ₹2,860.51 Cr | ₹2,658.74 Cr | ₹2,560.54 Cr | ₹2,385.1 Cr | ₹2,005.65 Cr |
| attributable to Owners | ₹2,714.03 Cr | ₹3,368.81 Cr | ₹3,117.95 Cr | ₹2,278.63 Cr | ₹2,149.88 Cr | ₹2,903.38 Cr | ₹3,040.16 Cr | ₹2,835.62 Cr | ₹2,654.58 Cr | ₹2,523.75 Cr | ₹2,375.51 Cr | ₹2,022.54 Cr |
| attributable to NCI | -₹4.37 Cr | ₹12.36 Cr | ₹7 Cr | ₹14.24 Cr | ₹4.05 Cr | ₹9.6 Cr | -₹2.83 Cr | ₹24.89 Cr | ₹4.16 Cr | ₹36.79 Cr | ₹9.59 Cr | -₹16.89 Cr |
| Other Comprehensive Income | ₹1,503.37 Cr | ₹780.52 Cr | ₹1,415.43 Cr | ₹127.42 Cr | ₹335.33 Cr | ₹117.94 Cr | ₹417.75 Cr | ₹41.39 Cr | ₹281.27 Cr | ₹424.94 Cr | ₹219.25 Cr | ₹216.67 Cr |
| Total Comprehensive Income | ₹4,213.03 Cr | ₹4,161.69 Cr | ₹4,540.38 Cr | ₹2,420.29 Cr | ₹2,489.26 Cr | ₹3,030.92 Cr | ₹3,455.08 Cr | ₹2,901.9 Cr | ₹2,940.01 Cr | ₹2,985.48 Cr | ₹2,604.35 Cr | ₹2,222.32 Cr |
| EBITDA (computed) | ₹4,412.7 Cr | ₹5,527.33 Cr | ₹4,996.97 Cr | ₹4,766.12 Cr | ₹4,328.96 Cr | ₹4,474.64 Cr | ₹4,292.96 Cr | ₹4,140.17 Cr | ₹3,641.09 Cr | ₹3,727.03 Cr | ₹3,472.99 Cr | ₹3,536.21 Cr |
| Basic EPS | ₹11.30 | ₹14.00 | ₹13.00 | ₹9.50 | ₹9.00 | ₹12.10 | ₹12.70 | ₹11.80 | ₹11.10 | ₹10.50 | ₹9.90 | ₹8.40 |
| Diluted EPS | ₹11.30 | ₹14.00 | ₹13.00 | ₹9.50 | ₹9.00 | ₹12.10 | ₹12.70 | ₹11.80 | ₹11.10 | ₹10.50 | ₹9.90 | ₹8.40 |
Latest 12 quarters shown of 25 on record.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹20,755 Cr | ₹23,003 Cr | ₹20,275 Cr | ₹20,812 Cr | ₹15,586 Cr | ₹12,803 Cr | ₹12,532 Cr |
| Other Income | ₹419.33 Cr | ₹369.43 Cr | ₹465.76 Cr | ₹279.03 Cr | ₹957.92 Cr | ₹150.22 Cr | ₹1,510.92 Cr |
| Total Income | ₹21,174 Cr | ₹23,373 Cr | ₹20,741 Cr | ₹21,091 Cr | ₹16,544 Cr | ₹12,953 Cr | ₹14,043 Cr |
| Cost of Materials Consumed | ₹4,383.27 Cr | ₹4,690.67 Cr | ₹4,429.38 Cr | ₹5,165.63 Cr | ₹4,584.97 Cr | ₹3,809.11 Cr | ₹3,201.71 Cr |
| Purchases of Stock-in-Trade | ₹1,391.52 Cr | ₹1,359.53 Cr | ₹994.41 Cr | ₹1,126.46 Cr | ₹1,248.6 Cr | ₹1,199.63 Cr | ₹1,227.41 Cr |
| Changes in Inventories | -₹305.83 Cr | -₹69.17 Cr | ₹180.32 Cr | -₹237.93 Cr | -₹183.18 Cr | -₹214.84 Cr | ₹138.6 Cr |
| Employee Benefit Expense | ₹2,911.3 Cr | ₹2,608.26 Cr | ₹2,373.95 Cr | ₹2,156.95 Cr | ₹2,000.78 Cr | ₹1,798.45 Cr | ₹1,702.77 Cr |
| Finance Costs | ₹947.84 Cr | ₹893.21 Cr | ₹784.08 Cr | ₹472.18 Cr | ₹388.1 Cr | ₹256.98 Cr | ₹408.01 Cr |
| Depreciation & Amortisation | ₹1,311.72 Cr | ₹1,238.27 Cr | ₹1,600.62 Cr | ₹1,600.87 Cr | ₹1,349.95 Cr | ₹586.81 Cr | ₹561.56 Cr |
| Other Expenses | ₹6,193.69 Cr | ₹7,621.42 Cr | ₹6,709.5 Cr | ₹6,128.17 Cr | ₹5,027.29 Cr | ₹3,274.86 Cr | ₹3,549.79 Cr |
| Total Expenses | ₹16,834 Cr | ₹18,342 Cr | ₹17,072 Cr | ₹16,412 Cr | ₹14,417 Cr | ₹10,711 Cr | ₹10,790 Cr |
| Profit Before Exceptional Items & Tax | ₹4,340.46 Cr | ₹5,030.57 Cr | ₹3,668.67 Cr | ₹4,678.84 Cr | ₹2,127.39 Cr | ₹2,242.43 Cr | ₹3,253 Cr |
| Exceptional Items | -₹546.34 Cr | ₹0 | -₹219.02 Cr | -₹2,937.79 Cr | -₹1,820.53 Cr | -₹89.56 Cr | ₹0 |
| Profit Before Tax | ₹3,794.12 Cr | ₹5,030.57 Cr | ₹3,449.65 Cr | ₹1,741.05 Cr | ₹306.86 Cr | ₹2,152.87 Cr | ₹3,253 Cr |
| Total Tax Expense | ₹1,170.7 Cr | ₹747.95 Cr | ₹591.47 Cr | ₹50.33 Cr | ₹406.85 Cr | ₹13.17 Cr | ₹41.86 Cr |
| Net Profit | ₹2,623.42 Cr | ₹4,282.62 Cr | ₹2,858.18 Cr | ₹1,690.72 Cr | -₹99.99 Cr | ₹2,139.7 Cr | ₹3,211.14 Cr |
| Other Comprehensive Income | -₹219.05 Cr | -₹23.2 Cr | -₹13.98 Cr | -₹11.01 Cr | -₹91.62 Cr | ₹63.3 Cr | -₹80.8 Cr |
| Total Comprehensive Income | ₹2,404.37 Cr | ₹4,259.42 Cr | ₹2,844.2 Cr | ₹1,679.71 Cr | -₹191.61 Cr | ₹2,203 Cr | ₹3,130.34 Cr |
| EBITDA (computed) | ₹6,600.02 Cr | ₹7,162.05 Cr | ₹6,053.37 Cr | ₹6,751.89 Cr | ₹3,865.44 Cr | ₹3,086.22 Cr | ₹4,222.57 Cr |
| Basic EPS | ₹10.90 | ₹17.80 | ₹11.90 | ₹7.00 | ₹-0.40 | ₹8.92 | ₹13.38 |
| Diluted EPS | ₹10.90 | ₹17.80 | ₹11.90 | ₹7.00 | ₹-0.40 | ₹8.92 | ₹13.38 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹43,060 Cr | ₹43,273 Cr | ₹41,065 Cr | ₹40,987 Cr |
| Non-current Assets | ₹26,350 Cr | ₹24,521 Cr | ₹26,110 Cr | ₹24,522 Cr |
| Current Assets | ₹16,679 Cr | ₹18,722 Cr | ₹14,913 Cr | ₹16,444 Cr |
| Property, Plant & Equipment | ₹5,145.4 Cr | ₹4,345.05 Cr | ₹4,539.14 Cr | ₹4,733.25 Cr |
| Inventories | ₹4,302.27 Cr | ₹3,787.49 Cr | ₹3,423.62 Cr | ₹3,989.19 Cr |
| Trade Receivables | ₹10,166 Cr | ₹11,701 Cr | ₹8,834.16 Cr | ₹7,125.02 Cr |
| Cash & Equivalents | ₹417.84 Cr | ₹492.02 Cr | ₹326.46 Cr | ₹410.28 Cr |
| Equity (Net Worth) | ₹22,371 Cr | ₹24,340 Cr | ₹23,694 Cr | ₹23,748 Cr |
| Equity Share Capital | ₹239.93 Cr | ₹239.93 Cr | ₹239.93 Cr | ₹239.93 Cr |
| Borrowings (Non-current) | ₹13,420 Cr | ₹0 | ₹11,036 Cr | ₹7,586.73 Cr |
| Borrowings (Current) | ₹0 | ₹10,954 Cr | ₹10.6 Cr | ₹5.94 Cr |
| Total Debt (computed) | ₹13,420 Cr | ₹10,954 Cr | ₹11,047 Cr | ₹7,592.67 Cr |
| Current Liabilities | ₹6,503.24 Cr | ₹18,149 Cr | ₹4,444.51 Cr | ₹8,365.44 Cr |
| Total Liabilities | ₹20,689 Cr | ₹18,934 Cr | ₹17,370 Cr | ₹17,239 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹6,500.87 Cr | ₹4,198.77 Cr | -₹292.42 Cr | ₹507.08 Cr | ₹7,636.36 Cr |
| Investing Cash Flow | -₹1,380.95 Cr | -₹209.56 Cr | -₹262.91 Cr | -₹705.17 Cr | -₹2,702.1 Cr |
| Financing Cash Flow | -₹5,230.18 Cr | -₹3,831.18 Cr | ₹473.95 Cr | ₹169.31 Cr | -₹4,870.85 Cr |
| Capital Expenditure | ₹1,542.78 Cr | ₹710.51 Cr | ₹749.24 Cr | ₹962.43 Cr | ₹849.9 Cr |
| Free Cash Flow (computed) | ₹4,958.09 Cr | ₹3,488.26 Cr | -₹1,041.66 Cr | -₹455.35 Cr | ₹6,786.46 Cr |
| Dividends Paid | ₹3,933.9 Cr | ₹3,613.97 Cr | ₹2,898.17 Cr | ₹2,518.88 Cr | ₹2,158.92 Cr |
| Net Change in Cash | -₹74.73 Cr | ₹165.56 Cr | -₹83.82 Cr | -₹9.25 Cr | ₹68.47 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹4,923.88 Cr | ₹5,687.77 Cr | ₹4,548.11 Cr | ₹5,601.96 Cr | ₹7,185.74 Cr | ₹6,191.81 Cr | ₹5,127.71 Cr | ₹4,498.07 Cr | ₹5,639.14 Cr | ₹5,073.75 Cr | ₹5,096.21 Cr | ₹4,466.07 Cr |
| Other Income | ₹62.93 Cr | ₹179.9 Cr | ₹72.79 Cr | ₹103.69 Cr | ₹132 Cr | ₹68.39 Cr | ₹86.3 Cr | ₹82.74 Cr | ₹118.88 Cr | ₹76.8 Cr | ₹106.54 Cr | ₹163.54 Cr |
| Total Income | ₹4,986.81 Cr | ₹5,867.67 Cr | ₹4,620.9 Cr | ₹5,705.65 Cr | ₹7,317.74 Cr | ₹6,260.2 Cr | ₹5,214.01 Cr | ₹4,580.81 Cr | ₹5,758.02 Cr | ₹5,150.55 Cr | ₹5,202.75 Cr | ₹4,629.61 Cr |
| Cost of Materials Consumed | ₹1,228.66 Cr | ₹1,160.49 Cr | ₹996.19 Cr | ₹1,067.24 Cr | ₹1,329.7 Cr | ₹1,162.73 Cr | ₹1,225.01 Cr | ₹973.23 Cr | ₹1,055.87 Cr | ₹1,121.64 Cr | ₹1,066.9 Cr | ₹1,184.97 Cr |
| Purchases of Stock-in-Trade | ₹311.91 Cr | ₹413.27 Cr | ₹338.09 Cr | ₹328.25 Cr | ₹325.7 Cr | ₹367.48 Cr | ₹360.09 Cr | ₹306.26 Cr | ₹289.5 Cr | ₹227.2 Cr | ₹264.65 Cr | ₹213.06 Cr |
| Changes in Inventories | -₹345.37 Cr | -₹68.96 Cr | ₹15.48 Cr | ₹95.92 Cr | -₹2.07 Cr | ₹131.29 Cr | -₹142.86 Cr | -₹55.53 Cr | -₹29.97 Cr | ₹129.13 Cr | ₹52.7 Cr | ₹28.46 Cr |
| Employee Benefit Expense | ₹703.99 Cr | ₹739.62 Cr | ₹728.77 Cr | ₹715 Cr | ₹648.91 Cr | ₹651.68 Cr | ₹662.19 Cr | ₹645.48 Cr | ₹575.97 Cr | ₹590.13 Cr | ₹600.41 Cr | ₹607.44 Cr |
| Finance Costs | ₹216.92 Cr | ₹244.17 Cr | ₹248.33 Cr | ₹223.29 Cr | ₹217.42 Cr | ₹215.96 Cr | ₹243.75 Cr | ₹216.08 Cr | ₹217.59 Cr | ₹214.92 Cr | ₹193.63 Cr | ₹157.94 Cr |
| Depreciation & Amortisation | ₹325.97 Cr | ₹338.53 Cr | ₹336.3 Cr | ₹299.03 Cr | ₹291.96 Cr | ₹290.97 Cr | ₹285.53 Cr | ₹369.81 Cr | ₹393.04 Cr | ₹399.6 Cr | ₹392.71 Cr | ₹415.27 Cr |
| Other Expenses | ₹1,695.72 Cr | ₹1,684.75 Cr | ₹1,285.99 Cr | ₹1,504.4 Cr | ₹1,894.04 Cr | ₹2,175.16 Cr | ₹1,684.66 Cr | ₹1,867.56 Cr | ₹1,854.24 Cr | ₹1,646.65 Cr | ₹1,725.23 Cr | ₹1,483.38 Cr |
| Total Expenses | ₹4,137.8 Cr | ₹4,511.87 Cr | ₹3,949.15 Cr | ₹4,233.13 Cr | ₹4,705.66 Cr | ₹4,995.27 Cr | ₹4,318.37 Cr | ₹4,322.89 Cr | ₹4,356.24 Cr | ₹4,329.27 Cr | ₹4,296.23 Cr | ₹4,090.52 Cr |
| Profit Before Exceptional Items & Tax | ₹849.01 Cr | ₹1,355.8 Cr | ₹671.75 Cr | ₹1,472.52 Cr | ₹2,612.08 Cr | ₹1,264.93 Cr | ₹895.64 Cr | ₹257.92 Cr | ₹1,401.78 Cr | ₹821.28 Cr | ₹906.52 Cr | ₹539.09 Cr |
| Exceptional Items | ₹0 | -₹258.7 Cr | ₹0 | -₹287.64 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹69.81 Cr | ₹0 | -₹149.21 Cr |
| Profit Before Tax | ₹849.01 Cr | ₹1,097.1 Cr | ₹671.75 Cr | ₹1,184.88 Cr | ₹2,612.08 Cr | ₹1,264.93 Cr | ₹895.64 Cr | ₹257.92 Cr | ₹1,401.78 Cr | ₹751.47 Cr | ₹906.52 Cr | ₹389.88 Cr |
| Total Tax Expense | ₹240.31 Cr | ₹391.66 Cr | ₹107.53 Cr | ₹431.35 Cr | ₹611.62 Cr | ₹83.88 Cr | ₹32.35 Cr | ₹20.1 Cr | ₹534.18 Cr | ₹30.16 Cr | ₹17.89 Cr | ₹9.24 Cr |
| Net Profit | ₹608.7 Cr | ₹705.44 Cr | ₹564.22 Cr | ₹753.53 Cr | ₹2,000.46 Cr | ₹1,181.05 Cr | ₹863.29 Cr | ₹237.82 Cr | ₹867.6 Cr | ₹721.31 Cr | ₹888.63 Cr | ₹380.64 Cr |
| Other Comprehensive Income | -₹142.69 Cr | ₹57 Lakh | -₹96.61 Cr | ₹19.27 Cr | ₹27.06 Cr | -₹47.44 Cr | -₹19.4 Cr | ₹16.58 Cr | -₹9.96 Cr | ₹6.26 Cr | -₹33.62 Cr | ₹23.33 Cr |
| Total Comprehensive Income | ₹466.01 Cr | ₹706.01 Cr | ₹467.61 Cr | ₹772.8 Cr | ₹2,027.52 Cr | ₹1,133.61 Cr | ₹843.89 Cr | ₹254.4 Cr | ₹857.64 Cr | ₹727.57 Cr | ₹855.01 Cr | ₹403.97 Cr |
| EBITDA (computed) | ₹1,391.9 Cr | ₹1,938.5 Cr | ₹1,256.38 Cr | ₹1,994.84 Cr | ₹3,121.46 Cr | ₹1,771.86 Cr | ₹1,424.92 Cr | ₹843.81 Cr | ₹2,012.41 Cr | ₹1,435.8 Cr | ₹1,492.86 Cr | ₹1,112.3 Cr |
| Basic EPS | ₹2.50 | ₹2.90 | ₹2.40 | ₹3.10 | ₹8.30 | ₹4.90 | ₹3.60 | ₹1.00 | ₹3.60 | ₹3.00 | ₹3.70 | ₹1.60 |
| Diluted EPS | ₹2.50 | ₹2.90 | ₹2.40 | ₹3.10 | ₹8.30 | ₹4.90 | ₹3.60 | ₹1.00 | ₹3.60 | ₹3.00 | ₹3.70 | ₹1.60 |
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Sun Pharmaceutical Industries Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Shareholding Pattern of Sun Pharmaceutical Industries Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 54.48%, foreign institutional investors hold 15.93%, domestic institutional investors hold 21.11%, retail and other public shareholders hold 8.48% of Sun Pharmaceutical Industries Limited. The company had 690,957 shareholders on record.
Mar 2026
QUARTER
54.48% Promoters
21.11% DII (Domestic Institutional)
15.93% FII (Foreign Institutional)
8.48% Retail & Others
Promoter holding - history
Now 54.48% · Mar 2026High 54.97% · Dec 2015Low 54.38% · Jun 2017
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| Public | 45.52% | 45.52% | 45.52% | 45.52% | 45.52% | 45.52% |
Shareholding history - year on year (as at 31 March)
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.69% | 54.38% | 54.38% | 54.39% | 54.97% |
| Public | 45.52% | 45.52% | 45.52% | 45.52% | 45.52% | 45.52% | 45.31% | 45.62% | 45.62% | 45.61% | 45.02% |
| Employee Trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | -0.21 | +0.31 | +0.00 | -0.01 | -0.58 | - |
Board & Governance of Sun Pharmaceutical Industries Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Sun Pharmaceutical Industries Limited has 8 directors - 4 independent and 4 executive. The board is chaired by Dilip Shantilal Shanghvi.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Dilip Shantilal Shanghvi | Executive Director · Chairperson | 1993-03-01 | 2 |
| Kirti Wardhaman Ganorkar | Executive Director · MD | 2025-09-01 | 1 |
| Pawan Kumar Goenka | Non-Executive - Independent Director | 2021-05-21 | 2 |
| Gautam Bhailal Doshi | Non-Executive - Independent Director | 2018-05-25 | 2 |
| Rama Bijapurkar | Non-Executive - Independent Director | 2021-05-21 | 4 |
| Rolf Hoffmann | Non-Executive - Independent Director | 2023-06-15 | 1 |
| Aalok Dilip Shanghvi | Executive Director | 2023-06-01 | 1 |
| Vidhi Dilip Shanghvi | Executive Director | 2025-05-22 | 2 |
Board Committees
| Committee | Members |
|---|---|
| Audit Committee | Gautam Bhailal Doshi (Chairperson), Pawan Kumar Goenka, Rama Bijapurkar |
| Nomination and remuneration committee | Pawan Kumar Goenka (Chairperson), Gautam Bhailal Doshi, Rolf Hoffmann, Dilip Shantilal Shanghvi |
| Stakeholders Relationship Committee | Gautam Bhailal Doshi (Chairperson), Pawan Kumar Goenka, Aalok Dilip Shanghvi, Kirti Wardhaman Ganorkar |
| Risk Management Committee | Pawan Kumar Goenka (Chairperson), Gautam Bhailal Doshi, Dilip Shantilal Shanghvi, Aalok Dilip Shanghvi, Jayashree Satagopan |
| Corporate Social Responsibility Committee | Rama Bijapurkar (Chairperson), Pawan Kumar Goenka, Dilip Shantilal Shanghvi, Vidhi Dilip Shanghvi |
| Corporate Governance and ESG Committee | Gautam Bhailal Doshi (Chairperson), Pawan Kumar Goenka, Kirti Wardhaman Ganorkar, Jayashree Satagopan, Anoop Deshpande |
Group Structure of Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has 14 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Sun Pharmaceutical Industries Limited's business expansion strategy and organizational complexity.
14
Subsidiary companies
1
Associated companies
Key Subsidiaries
| Company Name | CIN | Shares Held |
|---|---|---|
| Zenotech Laboratories Limited | L27100TG1989PLC010122 | - |
| Caraco Pharmaceuticals Private Limited | U24100MH2012FTC225970 | - |
| Vivaldis Health And Foods Private Limited | U24297PN2014PTC150393 | - |
| Sun Pharma Laboratories Limited | U25200GJ1997PLC133846 | - |
| Sun Pharmaceutical Medicare Limited | U36900GJ2017PLC095132 | - |
| Neetnav Real Estate Private Limited | U45200MH2010PTC201611 | - |
Showing major subsidiaries. Total: 14.
Charges & Borrowings of Sun Pharmaceutical Industries Limited
Open charges
₹16.06 Cr
Satisfied charges
₹1,785.22 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 May 1999 | Nvfc Finance Private Ltd | ₹75 Lakh | Open |
| 29 Apr 1999 | Risk Capital and Technology Finance Corporation Ltd | ₹1.5 Cr | Open |
| 17 Nov 1998 | Industrial Development Bank of India | ₹3.25 Cr | Open |
| 13 Sep 1996 | Industrial Development Bank of India | ₹9.2 Cr | Open |
| 11 Oct 1993 | Gujarat Industrial Investment Corporation Ltd. | ₹1.36 Cr | Open |
Total charge records: 38 View all charges
Employees and EPFO Compliance at Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has a workforce of 16,436 employees as of Oct 28, 2024.
Employee count
16,436
Active EPFO establishments
7
Employee growth
-15.94%
Premium access
Employee and EPFO history for Sun Pharmaceutical Industries Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Sun Pharmaceutical Industries Limited
Premium access
GST registrations and filing compliance for Sun Pharmaceutical Industries Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Sun Pharmaceutical Industries Limited
Premium access
Credit ratings, litigation, and regulatory alerts for Sun Pharmaceutical Industries Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sun Pharmaceutical Industries Limited
Premium access
MSME payment history for Sun Pharmaceutical Industries Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sun Pharmaceutical Industries Limited
Premium access
Corporate group structure for Sun Pharmaceutical Industries Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sun Pharmaceutical Industries Limited
Premium access
MCA filings and documents for Sun Pharmaceutical Industries Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Sun Pharmaceutical Industries Limited
Directors
12 May 2026
Andreas Eugen Busch was appointed as a Additional Director on 12 May 2026 & has been associated with this company since 2 months 11 days.
Directors
08 May 2026
Satyavati Berera was appointed as a Director on 08 May 2026 & has been associated with this company since 2 months 15 days.
Directors
01 Sep 2025
Kirti Wardhaman Ganorkar was appointed as a Managing Director on 01 Sep 2025 & has been associated with this company since 10 months 19 days.
Activity
31 Jul 2025
Sun Pharmaceutical Industries Limited last Annual general meeting of members was held on 31 Jul 2025 as per latest MCA records.
Directors
18 Jul 2025
Jayashree Satagopan was appointed as a Cfo on 18 Jul 2025 & has been associated with this company since 1 year 3 days.
Directors
22 May 2025
Vidhi Dilip Shanghvi was appointed as a Whole-time director on 22 May 2025 & has been associated with this company since 1 year 2 months.
Recent News on Sun Pharmaceutical Industries Limited
Frequently Asked Questions about Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 01 March 1993 (33+ years old) and is registered under CIN L24230GJ1993PLC019050. Listed on BSE: 524715 and NSE: SUNPHARMA. The company has 16,436 employees.
Sun Pharmaceutical Industries Limited reported revenue of ₹58,462 Cr for FY 2026 (up 11.19% YoY) based on consolidated NSE filings.
The current directors of Sun Pharmaceutical Industries Limited are:
- Pawan Kumar Goenka - Director
- Dilip Shantilal Shanghvi - Whole-Time Director
- Gautam Bhailal Doshi - Director
- Kirti Wardhaman Ganorkar - Managing Director
- Vidhi Dilip Shanghvi - Whole-Time Director
- Aalok Dilip Shanghvi - Whole-Time Director
- Rolf Karl Heinz Hoffmann - Director
- Satyavati Berera - Director
- Andreas Eugen Busch - Additional Director
The primary industry of Sun Pharmaceutical Industries Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Sun Pharmaceutical Industries Limited is listed on both BSE (code: 524715) and NSE (symbol: SUNPHARMA).
Sun Pharmaceutical Industries Limited can be reached at the registered office: Sparc Tandalja, Vadodara, Gujarat, India – 390012, or through the website sunpharma.com.